Skin and skin structure infections: treatment with newer generation fluoroquinolones

Reference

• AmankwaKKrishnanSCTisdaleJETorsades de pointes associated with fluoroquinolones: importance of concomitant risk factorsClin Pharmacol Ther200475242715001976
   PubMed Web of Science ®Google Scholar
• AnzuetoANiedermanMSPearleJCommunity acquired pneumonia recovery in the elderly (CAPRIE): eff icacy and safety of moxifloxacin therapy versus that of levofloxacin therapyClin Infect Dis200642738116323095
   PubMed Web of Science ®Google Scholar
• [AMR] Arlington Medical ResourcesHospital Antibiotic Market Database [online]2004 Accessed on 25 July 2006. URL: http://www.amr-data.com/
   Google Scholar
• BallPStahlmanRKubinRSafety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studiesClin Ther2004269405015336463
   PubMed Web of Science ®Google Scholar
• BallPQuinolone-induced QT interval prolongation: a not-so-unexpected class effectJ Antimicrob Chemother200045557910797074
   PubMed Web of Science ®Google Scholar
• Bayer Pharmaceuticals Co.Avelox (moxifloxacin) package insert2005Westhaven, CTBayer Pharmaceuticals
   Google Scholar
• BignardiGERisk factors for Claustridium difficile infectionJ Hosp Infect1998401159777516
   PubMed Web of Science ®Google Scholar
• BertinoJSOwensRCJrCarnesTDGatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factorsClin Infect Dis200234861311830802
   PubMed Web of Science ®Google Scholar
• BlondeauJMHansenGMetzlerKLIn vitro susceptibility of 4903 bacterial isolates to gemifloxacin and advanced fluoroquinolonesInt J Antimcrob Agents20032214754
   PubMedGoogle Scholar
• Bristol-Myers Squibb Co.Tequin (gatifloxacin) package insert2006aPrinceton, NJBristol-Myers Squibb Co
   Google Scholar
• Bristol-Myers Squibb Co.Dear Health Care Provider letter [online]2006b Accessed 10 April 2006. URL: http://www.fda.gov/medWatch/safety/2006/tequin_DHCP.pdf
   Google Scholar
• [CDC] Center for Disease ControlIncidence of soft tissue infections: San Francisco General Hospital––1996–2000MMWR200150381411465906
   PubMedGoogle Scholar
• [CLSI] Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing2006 Sixteenth Informational Supplement. CLSI document M100–S16
   Google Scholar
• DialSAlrasadiKHuangARisk of Clostridium dificile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studiesCan Med Assoc J200417133815238493
   PubMed Web of Science ®Google Scholar
• DiNubileMJLipskyBAComplicated Infections of skin and skin structure infections: When infection is more than skin deepJ Antimicrob Chemother2004533750
   Web of Science ®Google Scholar
• EdmistonCEKrepelCJSeabrookGRIn vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infectionsAntimicrob Agents Chemother20044810121614982797
   PubMed Web of Science ®Google Scholar
• [EMEA] European Agency for the Evaluation of Medicinal Products; Committee for Proprietary Medicinal ProductsPoints to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products [online]2006 Accessed 10 April 2006. URL: http://www.coresearch.biz/regulations/cpmp.pdf
   Google Scholar
• [FDA] Food and Drug AdministrationGuidance for industry: uncomplicated skin and skin structure infections––Developing antimicrobial drugs for therapy [online]1998 Accessed 10 April 2005. URL: http://www.fda.gov/cder/guidance/2566dft.pdf
   Google Scholar
• FiebelkornKRCrawfordSAMcElmeelMLPractical disc diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococciJ Clin Microbiol2003414740414532213
   PubMed Web of Science ®Google Scholar
• FileTMJrTanJSTreatment of skin and soft-tissue infectionsAm J Surgery19951695A Suppl27S33S
   PubMedGoogle Scholar
• FirsovAALubenkoIYVostrovSNAntistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolonesAntimicrob Agents Chemother2005492642715980331
   PubMedGoogle Scholar
• ForrestANixDEBallowCHPharmocodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrob Agents Chemother1993371073818517694
   PubMed Web of Science ®Google Scholar
• FrazeeBWLynnJCharleboisEDHigh prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infectionsAnn Emerg Med2005453112015726056
   PubMed Web of Science ®Google Scholar
• FurlanutMBrolloLLugattiEPharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infectionsJ Antimicrob Chemother200351101612493793
   PubMed Web of Science ®Google Scholar
• GandhiPJMenezesPAVuHTFluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patientAm J Health-Syst Pharm20036024798314686224
   PubMed Web of Science ®Google Scholar
• GerdingDNClindamycin, cephalosporins, fluoroquinolones, and Claustridium difficile-associated: this is an antimicrobial resistance problemClin Infect Dis200438646814986247
   PubMed Web of Science ®Google Scholar
• GiordanoPSongJPertelPSequential intravenous/oral moxifloxacin versus intravenous pipericillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionInter J Antimicro Agents20052635765
   PubMed Web of Science ®Google Scholar
• GraffunderEMVeneziaRARisk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobialsJ Antimicrob Chemother200249999100512039892
   PubMed Web of Science ®Google Scholar
• GrahamDRTalanDANicholsRLOnce-daily, high dose levofloxacin versus ticaricillin-clavulanate alone or followed by amoxicillin for complicated skin and skin structure infections: A randomized, open label trialClin Inf Dis2002353819
   PubMed Web of Science ®Google Scholar
• GuayDTreatment of bacterial skin and skin structure infectionsExpert Opin Pharmacother2003412597512877635
   PubMed Web of Science ®Google Scholar
• HagiwaraTSatohSKasaiYA comparative study of the various fluoroquinolone antibacterial agents on the cardiac action potential in guinea pig right ventricular myocardiumJpn J Pharmacol200187231411885973
   PubMedGoogle Scholar
• IanniniPBCirciumaruIGatifloxacin-induced QTc prolongation and ventricular tachycardiaPharmacotherapy20012136111253862
   PubMed Web of Science ®Google Scholar
• JohnsonSGerdingDNClostridium difficile-associated diarrheaClin Infect Dis1998261027349597221
   PubMed Web of Science ®Google Scholar
• LeeMCRiosAMAtenMFManagement and outcomes of skin and soft tissue abcesses coused by community acquired methicillin resistant Staphylococcus aureusPediatri Infect Dis J2004231237
   PubMed Web of Science ®Google Scholar
• LooVGPoirierLMillerMAA predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortalityN Engl J Med2005353232442916322602
   PubMed Web of Science ®Google Scholar
• LubaschAKellerIBornerKComparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteersAntimicrob Agents and Chemother2000442600310991830
   PubMed Web of Science ®Google Scholar
• ManholdCvon RolbiekiUBraseROutbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective randomized studyIntensive Care Med1998241327309885888
   PubMedGoogle Scholar
• MilatovicDSchmitzFBrisseSIn vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolatesAntimicrob Agents Chemother2000441102710722524
   PubMed Web of Science ®Google Scholar
• MulliganMEMillerSDMcFarlandElevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficileClin Infect Dis199316suppl 4S239448324125
   PubMed Web of Science ®Google Scholar
• NaimiTSLeDellKHComo-SabettiKComparison of community- and health care-acquired methicillin resistant Staphylococcus aureus infectionJAMA200329029768414665659
   PubMed Web of Science ®Google Scholar
• NicholsRLSmithJWGentryLOMulti-center, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infectionsSouth Med J19979011932009404904
   PubMed Web of Science ®Google Scholar
• NicholsRLOptimal treatment of complicated skin and skin structure infectionsJ Antimicrob Chemother199944192310511393
   PubMed Web of Science ®Google Scholar
• NoelARBowkerKEMacgowanAPPharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic modelAntimicrob Agents Chemother2005494234916189103
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil PharmaceuticalLevaquin (levofloxacin) package insert2005Raritan, NJ
   Google Scholar
• OwensRCRisk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointesPharmacotherapy2001213011911253855
   PubMed Web of Science ®Google Scholar
• OwensRCQT prolongation with antimicrobial agents: understanding the signif icanceDrugs200464109112415139788
   PubMed Web of Science ®Google Scholar
• OwensRCClaustridium difficile-associated disease: An emerging threat to patient safetyPharmacotherapy200626329931116503710
   PubMed Web of Science ®Google Scholar
• ParishLCRouthHBMiskinBMoxifloxacin versus cephalexin in the treatment of uncomplicated skin infectionsInt J Clin Pract20005449750311198726
   PubMed Web of Science ®Google Scholar
• RaghavanRLindenPKNewer treatment options for skin and soft tissue infectionsDrugs20046416214215257625
   PubMed Web of Science ®Google Scholar
• RennieRPJonesRNMutnickAHOccurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the Sentry antimicrobial surveillance programDiagn Microbio Infect Dis20034528793
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541137340616231249
   PubMed Web of Science ®Google Scholar
• TarshisGAMiskinBMJonesTMOnce-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized studyAntimicrob Agents Chemother20014523586211451697
   PubMed Web of Science ®Google Scholar
• TrampuzALaiferGPharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluidAntimicrob Agents Chemother2002463630312384378
   PubMedGoogle Scholar
• TrampuzAWenkMRajacicZPharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluidAntimicrob Agents Chemother2000441352510770776
   PubMedGoogle Scholar
• WeberSGGoldHSHooperDCFluoroquinolones and the risk of methicillin resistant Staph aureus in hospitalized patientsEmerg Infect Dis2003914152214718085
   PubMed Web of Science ®Google Scholar
• WickershamRMSchweainSLDrug facts and comparisons2005St. LouisWolters Kluwer Health, Inc
   Google Scholar
• WiseRAndrewsJMMarshallGPharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral and intravenous administrationAntimicrob Agents and Chemother19994315081010348784
   PubMed Web of Science ®Google Scholar
• WrightDHBrownGHPetersonMLApplication of fluoroquinolone pharmacodynamicsJ Antimocrob Chemother20004666983
   PubMed Web of Science ®Google Scholar
• YapYGCammAJDrug-induced QT prolongation and torsades de pointesHeart20038913637214594906
   PubMed Web of Science ®Google Scholar
• YeeSYKutiJLNicolauDPAntimicrobial management of complicated skin and skin structure infections in the era of emerging resistanceSurg Infect2005628395
   PubMedGoogle Scholar